Spots Global Cancer Trial Database for tigit
Every month we try and update this database with for tigit cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours | NCT05607563 | Advanced Tumor | PM1009 injectio... | 18 Years - 75 Years | Biotheus Inc. | |
| Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer | NCT05809895 | Triple Negative... | Ociperlimab Tislelizumab Paclitaxel Nab-paclitaxel Carboplatin Placebo Pembrolizumab Gemcitabine | 18 Years - | Novartis | |
| Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer | NCT05809895 | Triple Negative... | Ociperlimab Tislelizumab Paclitaxel Nab-paclitaxel Carboplatin Placebo Pembrolizumab Gemcitabine | 18 Years - | Novartis | |
| Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma | NCT05289492 | Multiple Myelom... | EOS884448 Iberdomide Dexamethasone | 18 Years - | iTeos Therapeutics | |
| Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) | NCT03739710 | Neoplasms | Docetaxel Feladilimab Ipilimumab GSK4428859A Dostarlimab GSK6097608 | 18 Years - | GlaxoSmithKline | |
| AB154 Combined With AB122 for Recurrent Glioblastoma | NCT04656535 | Glioblastoma | AB122 AB154 Placebo | 18 Years - | Yale University | |
| Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma | NCT05289492 | Multiple Myelom... | EOS884448 Iberdomide Dexamethasone | 18 Years - | iTeos Therapeutics | |
| Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) | NCT04585815 | Carcinoma, Non-... | Sasanlimab Pref... Encorafenib Binimetinib Sasanlimab Axitinib SEA-TGT | 18 Years - | Pfizer | |
| GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers | NCT03198052 | Lung Cancer Cancer Immunotherapy CAR-T Cell | CAR-T cells tar... | 18 Years - 75 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) | NCT03739710 | Neoplasms | Docetaxel Feladilimab Ipilimumab GSK4428859A Dostarlimab GSK6097608 | 18 Years - | GlaxoSmithKline | |
| A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours | NCT05607563 | Advanced Tumor | PM1009 injectio... | 18 Years - 75 Years | Biotheus Inc. | |
| Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors | NCT05060432 | Advanced Cancer Lung Cancer Head and Neck C... Melanoma | EOS-448 pembrolizumab inupadenant Dostarlimab SOC chemotherap... | 18 Years - | iTeos Therapeutics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
